Divalproex PCD Pharma Franchise Company
Cafoli Lifecare offers a Divalproex range of 4 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving neurology and psychiatry prescribers can secure district-wise monopoly franchise rights for this established anti-epileptic and mood stabiliser with full promotional support.
What is Divalproex?
Divalproex sodium is a stable compound of valproic acid and sodium valproate that increases brain levels of the inhibitory neurotransmitter GABA. It controls seizures, stabilises mood in bipolar disorder and prevents migraine. Reference: PubChem - Divalproex sodium.
Available Forms
The Cafoli Divalproex portfolio is offered as oral extended- and delayed-release Tablets in the commonly prescribed strengths (250mg, 500mg). Contact us for current pack presentations and combinations.
Therapeutic Applications
Divalproex is prescribed for epilepsy and various seizure types, acute mania and maintenance in bipolar disorder, and the prophylaxis of migraine. Prescribers include neurologists, psychiatrists, paediatric neurologists and physicians.
Why Divalproex is a High-Potential Molecule for Distributors
Epilepsy, bipolar disorder and migraine all require long-term, often lifelong therapy, and divalproex is a cornerstone molecule across all three, giving it a broad neuro-psychiatry prescriber base. Chronic daily dosing translates into steady, predictable monthly refill volume for distributors serving these specialties.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Divalproex sodium
- MedlinePlus: Valproic acid / divalproex
- WHO Essential Medicines List - valproic acid
Our formulations of Divalproex find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: